Jerusalem-based biotech Tiltan has raised $1.5 million for the completion of its on-going Phase II clinical study of TL-118, an anti-angiogenic therapy for treating metastatic pancreatic cancer. 80 patients are being tested in seven major Israeli oncology centers and also two in the US.
http://www.globes.co.il/en/article-pancreatic-cancer-treatment-co-tiltan-pharma-raises-15m-1000915007